Using Rimegepant to treat migraine in real-world settings
A Prospective Real World Study of Rimegepant in the Treatment of Migraine
This study is testing how well Rimegepant works for people with migraines in everyday life and if it's safe to use.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine Academic / other |
| Locations | 1 site (Boao, Hainan) |
| Trial ID | NCT05709106 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness and safety of Rimegepant for treating migraine patients in real-world conditions. Participants will take Rimegepant as needed for migraine attacks and will record their experiences, including efficacy and any adverse events, at specified intervals. Additionally, they will track their monthly migraine days and complete patient-reported outcomes during follow-ups to assess long-term treatment effects.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with migraines who are prescribed Rimegepant.
Not a fit: Patients with severe cognitive impairments or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the real-world effectiveness of Rimegepant for migraine management.
How similar studies have performed: Other studies have shown promise in using Rimegepant for migraine treatment, but this specific observational approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects diagnosed as migraines (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, beta version * Rimegepant is prescribed by the physician for the treatment of patients with migraine. * Patients signed written informed consent. * Male and Female subjects ≥ 18 years and older * Patients is not participated in other concurrent interventional clinical studies. Exclusion Criteria: * The patients with severe visual, hearing, language, intelligence, memory, and consciousness disorders, are unable to cooperate with the completion of the questionnaire and follow-up. * Pregnant patients * Lactating female patients * Patients who are highly dependent on medical care.
Where this trial is running
Boao, Hainan
- Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine — Boao, Hainan, China (Recruiting)
Study contacts
- Principal investigator: Jun Liu — Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine
- Study coordinator: Wenyan Kang
- Email: kwymed22@163.com
- Phone: +86 13816512546
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.